Raise the Line

“I'm betting it's going to be more good than bad, but I have some big concerns about where things are headed,” warns Dr. Matthew Johnson of Johns Hopkins University when prognosticating about what impact the use of psychedelics in mental health treatment will have on society at large. As he tells host Shiv Gaglani, once these compounds are more widely available, there is real potential for unscrup...

For our 400th episode we’re happy to be diving into one of our favorite topics -- direct-to-consumer healthcare -- with a leading force in the space, Dr. Kapil Parakh. In his role as senior medical lead at Google, Dr. Parakh has led projects to expand access to health information and help people achieve their fitness goals using Fitbit and other means. He’s also helped launch products that reach a...

“We don't have a shortage of nurses in this country. We have a shortage of nurses willing to practice in the healthcare environments as they are today,” says Rebecca Love, an educator, innovator and leader who has devoted her career to improving the profession of nursing from multiple angles. She’s currently pursuing one of those efforts as chief clinical officer at IntelyCare, an app which smooth...

Twenty years ago, health outcomes in Eastern North Carolina lagged behind state averages but those deficits have largely been erased, and Dr. Mike Waldrum, Dean of the Brody School of Medicine at East Carolina University, thinks he knows why. “We’ve done it primarily with a community-based focus and taking students only from North Carolina that we know have a propensity to want to practice medicin...

If you were to make a word cloud based on this episode of Raise the Line , community would be the most prominent term.  For starters, Dr. Allison Brashear was attracted to Buffalo for its reputation as a welcoming community -- a city of good neighbors, as she puts it -- which reminded her of her roots in the Midwest.  She was also encouraged that the University at Buffalo Jacobs School of Medicine...

“We thought it was the end of psychedelic research, and the great dreams we had were for some future generation,” says Dr. Bill Richards, referring to the 1970s when the Nixon administration criminalized psychedelic compounds.  At that point, he could not have imagined there would once again be the thriving interest in psychedelics for both therapeutic and non-clinical purposes that we see today....

“After an hour in this machine, I learned more about my health than the health system had told me my entire life.” That’s our Raise the Line guest Andrew Lacy describing a full body MRI scan he underwent several years ago in Canada that sparked the idea for the company he subsequently founded, Prenuvo, which uses advanced MRI technology for preventive screenings. Growing curiosity about the state...

When Tracy Dixon-Salazar was a young mother of two she described herself as a mediocre high school student with no real academic or career ambitions. Today, she has a PhD in Neurobiology and Neurosciences, is credited with uncovering the genetic driver of a rare form of childhood-onset epilepsy, and she also identified the first precision therapy for it. Unfortunately, the spark for this remarkabl...

“There's never been a better time to do what we do in our fields and the future of life sciences is so incredibly bright,” says Dr. Lloyd Minor. From his perch as dean of Stanford University School of Medicine, Minor sees the convergence of biomedicine, information science and technology dramatically increasing the pace of discovery-driven science and translational science. As a result of observin...

Educating someone to be a nurse, physician or allied health professional is obviously a complex process for learners, faculty and administrators. Today, our new Raise the Line co-host (and Osmosis COO) Derek Apanovitch takes a look at tools that help all of those stakeholders visualize the overall curriculum, where a student is on their learning path, and how they are performing. Our guide is Andr...

The failure of patients to take their medications as prescribed costs the U.S. healthcare system more than $500 billion a year, not to mention the adverse health outcomes it causes. Today’s Raise the Line guest, Sebastian Seiguer, co-founded and leads a company called Scene Health that is tackling this problem with a system that combines video technology, clinical coaching and validated interventi...

To the uninitiated, interoperability may sound like a surgical term, but it actually refers to how IT systems and other technologies communicate with each other. The goal, of course, is seamless communication to improve efficiency and quality of care, but that's obviously a big challenge. Today on Raise the Line , we dive into this important issue with two people who come at it from different prof...

Dr. David Yaden’s interest in studying spiritual experiences started with one of his own. As he describes it, it was a totally spontaneous experience involving an intensely altered state of consciousness that left him with an enhanced, positive perspective on life. “This became an obsession, really, to understand this. I learned that these experiences have been studied throughout history by schola...

“I think we're doing something really special here to change the way healthcare is delivered in South Florida, so keep an eye on us,” says Dr. Julie Pilitsis, dean of the Charles E. Schmidt College of Medicine and Vice President of Medical Affairs at Florida Atlantic University. For one thing, class sizes in the medical and nursing programs are both increasing to tackle less than ideal access to h...

Shortly after starting his job as Dean of the USF Health Morsani College of Medicine in 2014, Dr. Charles Lockwood was presented with the exciting opportunity to help design a new medical education building. In contemplating requirements for the new space, he raised the challenge to colleagues that when the facility was completed in 2020, medical knowledge would be doubling every seventy-three day...

After battling chronic illness as a child, Dr. Janelle Sokolowich swore she’d never step foot in a hospital again and started pursuing a different path in college. But life had a way of bringing her back to the world of medicine. “I started thinking back to all the nurses that made such an impact on me as a child and helped me to grow up to be a functioning adult,” she explains to host Michel Carr...

Major depression, smoking, anorexia nervosa, obsessive-compulsive disorder, Alzheimer’s disease...is it possible for psychedelics to play a positive role in all of these conditions? There are indications the answer may be yes, which is why Dr. Al Garcia-Romeu and his colleagues at The Johns Hopkins Center for Psychedelic and Consciousness Research are so busy. “We're learning more, but as we learn...

When Deepak Thomas contracted Lyme disease in his twenties, he quickly discovered how difficult it can be for a person to navigate the healthcare system, particularly when filling prescriptions. “When it came to accessing medications that could keep me healthy and eventually kick this condition, I found myself making three to four trips to the pharmacy every week, despite being covered by a genero...

As our Year of the Zebra focus on rare diseases continues, we’re putting several neurological conditions in the spotlight whose symptoms include neck pain, vertigo, swallowing issues, memory trouble and many more: idiopathic syringomyelia; idiopathic scoliosis; and the Arnold-Chiari Syndrome type 1 caused variously by cavities in the spinal cord and brain herniation. Fortunately, our guide is one...

In this episode of Raise the Line , we dive into the fascinating story of a very old technology, EEGs, being mined for data using a very new technology, AI, that's changing the way treatments are being developed for disorders of the brain. Joining host Michael Carrese to explain is Dr. Jake Donoghue, co-founder and CEO of Beacon Biosignals, a startup that’s using AI to unlock precision medicine fo...

If psychedelics are eventually authorized by the FDA for use in mental health treatment, much credit will go to The Johns Hopkins Center for Psychedelic and Consciousness Research which sparked a renaissance of interest in the compounds starting in 2006 under the guidance of Dr. Roland Griffiths. The first study was actually not about clinical applications of hallucinogens but rather it observed t...

“The unifying theme across our portfolio is that whatever a company we invest in is building can make a population-level health impact. For us, that means that what they're doing is going to lead to innovation that is ultimately accessible to huge portions of the global population,” says Gurdane Bhutani, co-founder and managing partner of MBX Capital, a venture capital partnership dedicated to inv...

One challenge in developing treatments for rare diseases is finding enough people with the condition to mount valid clinical trials.  Databases that contain diagnostic codes for specific conditions can help, but those miss people who may have the condition but have yet to be conclusively diagnosed.  That’s where Verana Health comes in, a digital health company that uses AI to mine its data network...

“In 2010, it took three-and-a-half years for medical knowledge to double. Now it takes around seventy-three days,” says Dr. Ted O’Connell, who is among the many medical educators who wrestle with how to help students manage that kind of information load. Artificial intelligence can be a tool for synthesizing vast amounts of data, he says, but it also has the potential to massively increase the amo...

We've heard many stories on Raise the Line about patients and their family members who, upon getting a rare disease diagnosis, build a non-profit organization from scratch to boost advocacy and research for the condition in question. This is obviously a pretty big hill to climb for people with no background in such things. Well, today we're going to learn about Beacon for Rare Diseases, a UK non-p...